| Loxo Oncology–Lilly: investment, 201901–201902 acquisition cash tender offer $8b for $235/share |
2019-01-07 |
| N-of-One–Qiagen: investment, 201901 acquisition €na of N-of-One Inc by Qiagen |
2019-01-07 |
| Roche–Exscientia: drug discovery software, 201901– collab up to CHF67m + royalties using Centaur Chemist to design drug candidates |
2019-01-07 |
| Biogen–C4 Therapeutics: neurological drugs, 201901– collab strategic up to $415m upfront/milestones discovery small molecues for protein degradation |
2019-01-04 |
| Biogen–Skyhawk Therapeutics: neurological drugs, 201901– collab strategic $74m upfront + milestones discovery small molecues using SkySTAR platform |
2019-01-04 |
| Medigene–Helmholtz: cell therapy, 201901– license to co-stimulator to enhance TCR therapies for solid tumours from HMGU |
2019-01-04 |
| Ribon Therapeutics–Celgene: investment, 201901 financing round Series B totalling $65m incl new + co-investor Celgene Corp |
2019-01-04 |
| Ribon Therapeutics–Column Group: investment, 201901 financing round Series B totalling $65m incl existing + co-investor The Column Group |
2019-01-04 |
| Ribon Therapeutics–Deerfield: investment, 201901 financing round Series B totalling $65m incl existing + co-investor Deerfield Management |
2019-01-04 |
| Ribon Therapeutics–Euclidean Capital: investment, 201901 financing round Series B totalling $65m incl existing + co-investor Euclidean Capital |
2019-01-04 |
| Ribon Therapeutics–JnJ: investment, 201901 financing round Series B totalling $65m incl new + co-investorJJDC |
2019-01-04 |
| Ribon Therapeutics–Novartis: investment, 201901 financing round Series B totalling $65m incl new + lead investor Novartis Venture Fund |
2019-01-04 |
| Ribon Therapeutics–Osage Partners: investment, 201901 financing round Series B totalling $65m incl existing + co-investor Osage University Partners |
2019-01-04 |
| Ribon Therapeutics–SEVERAL: investment, 201901 financing round Series B $65m led by Novartis Venture Fund |
2019-01-04 |
| Ribon Therapeutics–Takeda: investment, 201901 financing round Series B totalling $65m incl existing + co-investor Takeda Ventures |
2019-01-04 |
| Ribon Therapeutics–US Venture Partners: investment, 201901 financing round Series B totalling $65m incl existing + co-investor US Venture Partners |
2019-01-04 |
| Sophia Genetics–Alychlo: investment, 201901 financing round Series E totalling $77m incl existing + co-investor Alychlo |
2019-01-04 |
| Sophia Genetics–Balderton Capital: investment, 201901 financing round Series E totalling $77m incl existing + co-investor Balderton Capital |
2019-01-04 |
| Sophia Genetics–Eurazeo: investment, 201901 financing round Series E totalling $77m incl new + co-investor Idinvest Partners |
2019-01-04 |
| Sophia Genetics–Generation Investment Management: investment, 201901 financing round Series E totalling $77m incl new + lead investor Generation |
2019-01-04 |
| Sophia Genetics–SEVERAL: investment, 201901 financing round Series E $77m incl new + lead investor Generation Investment Management LLP |
2019-01-04 |
| Atriva Therapeutics–High-Tech Gründerfonds: investment, 201901 financing round Series A first closing led by Meneldor + HTGF |
2019-01-03 |
| Atriva Therapeutics–MC Services: public relations, 201901 service existent by MC Services |
2019-01-03 |
| Atriva Therapeutics–Meneldor: investment, 201901 financing round Series A first closing led by Meneldor + HTGF |
2019-01-03 |
| Atriva Therapeutics–SEVERAL: investment, 201901 financing round Series A first closing led by Meneldor + HTGF |
2019-01-03 |
| Takeda–Rentschler: biologics contract manufacturing, 201901– supply service continued production for Shire in acquired manufacturing site in Milford |
2019-01-03 |
| CARB-X–Germany (govt): grant, 201901–202212 BMBF commits €40m over 4 years |
2019-01-01 |
| Curetis–Vienna (govt): grant, 201901–202106 co-funding of developm project of Ares Genetics for AMR assay by Vienna Business Agency |
2019-01-01 |
| Delfi Diagnostics–Allianz: investment, 2019 seed financing round totalling $5.5m incl co-investor AV8 Ventures |
2019-01-01 |
| Delfi Diagnostics–SEVERAL: investment, 2019 seed financing round $5.5m led by Menlo Ventures |
2019-01-01 |
| Marinomed–EU (govt): credit, 20901–2027 up to €15m EIB credit 2019–2022 repayable 2024–2027 |
2019-01-01 |
| Medicomp–KLIFO: investment, 2019 acquisition of Medicomp GmbH by KLIFO A/S |
2019-01-01 |
| Blink Biomedical–Valneva: investment, 201812 existing shareholding of 43.3% by Valneva consolidated via equity method |
2018-12-31 |
| Murdoch Univ–Bruker: mass spectrometer, 2018–201909 supply FIA-MRMS system |
2018-12-31 |
| Murdoch Univ–Bruker: mass spectrometer, 2018–201909 supply twelve impact-II UHR-QTOF LC-MS/MS systems |
2018-12-31 |
| Murdoch Univ–Bruker: mass spectrometer, 2018–201909 supply two timsTOF Pro LC/CCS/MS/MS systems |
2018-12-31 |
| Murdoch Univ–Bruker: NMR spectrometer, 2018–201909 supply seven Avance IVDr 600 NMR systems |
2018-12-31 |
| Qiagen–Formulatrix: digital PCR technology, 201812– acquisition of all dPCR assets of Formulatrix for $125m upfront cash + $135m milestones |
2018-12-31 |
| Harpoon Therapeutics–SEVERAL: investment, 201812–201902 IPO $76m at $14/share |
2018-12-27 |
| Nabriva–Hercules Capital: credit, 201812–202306 term loan up to $75m with $25m up front von Hercules Capital |
2018-12-21 |
| Evitria–Afinum: investment, 201812 acquisition majority stake by Afinum Achte Beteiligungs GmbH & Co KG + SHS V Medtech Investments GmbH |
2018-12-20 |
| Evitria–SHS Capital: investment, 201812 acquisition majority stake by Afinum Achte Beteiligungs GmbH & Co KG + SHS V Medtech Investments GmbH |
2018-12-20 |
| France (govt)–Novartis: investment, 201812– proposed acquisition of CellforCure from LFB by Novartis |
2018-12-20 |
| AC Immune–WuXi Pharmatech: biologics contract manfucturing, 201812– collab strategic alliance biologics CDMO with WuXi Biologics |
2018-12-19 |
| Annexon–Novartis: investment, 201812 financing round Series C totalling $75m incl exisiting + co-investor NVF |
2018-12-19 |
| Annexon–SEVERAL: investment, 201812 financing round Series C $75m led by new investor Bain Capital Life Sciences |
2018-12-19 |
| Cellestia Biotech–PPF Group: investment, 201812 financing round Series A totalling CHF20m incl existing + co-lead investor Sotio/PPF Group |
2018-12-19 |
| Cellestia Biotech–SEVERAL: investment, 201812 financing round Series A CHF20m from FC Capital + Sotio/PPF Group + ETP Ventures + private investors |
2018-12-19 |
| Amgen–Molecular Partners: cancer immunotherapy, 201812– collab $50m upfront + $497m milestones + royalties ww excl developm + commerc rights to MP0310 |
2018-12-18 |
| Novartis–Curetis: antibiotics research, 201812– collab Sandoz to use Ares Genetics’ antibiotic resistance database ARESdb |
2018-12-18 |
| PreOmics–High-Tech Gründerfonds: investment, 201812 financing round Series A totalling €3.3m incl HTGF + Think.Health Ventures + business angels |
2018-12-18 |
| PreOmics–SEVERAL: investment, 201812 financing round Series A €3.3m from HTGF + Think.Health Ventures + business angels |
2018-12-18 |
| PreOmics–Think.Health Ventures: investment, 201812 financing round Series A totalling €3.3m incl HTGF + Think.Health Ventures + business angels |
2018-12-18 |
| Versameb–SEVERAL: investment, 201812 colsing of seed B financing round brining total capital raised to date to CHF5.3m |
2018-12-18 |
| Seer–Invus Group: investment, –201812 financing rounds Series A + B totalling $36m incl Series B lead investor Invus |
2018-12-17 |
| Seer–Maverick Ventures: investment, –201812 financing rounds Series A + B totalling $36m incl Series A lead investor Maverick Ventures |
2018-12-17 |
| Seer–SEVERAL: investment, –201812 financing rounds Series A + B of $36m until 12/18 as company emerges from stealth |
2018-12-17 |
| Shire–Rentschler: investment, 201812–201901 acquisition €na of Shire’s manufacturing facility in Milford, MA by Rentschler Biopharma SE |
2018-12-17 |
| Orchard Therapeutics–Sirion Biotech: gene therapy manufacturing technology, 201812– license for stem cell gene therapies |
2018-12-14 |
| Lonza–ERS Genomics: CRISPR technology, 201812– license €na for bioproduction products + services + iPSC research to Lonza Pharma & Biotech |
2018-12-13 |
| Mestrelab Research–Bruker: investment, 201812 acquisition of majority share €na by Bruker incl strateg collab + partnership |
2018-12-13 |
| AC Immune–Lilly: credit, 201812 convertible note $50m in connection with license + collab agreement |
2018-12-12 |
| Imprint Analytics–SGS: credit, 201812– convertible loan as part of strategic partnership |
2018-12-12 |
| Lilly–AC Immune: tau aggregation inhibitors, 201812– collab + license agreem CHF80m upfront + CHF1.76b milestones + royalties |
2018-12-12 |
| Santhera–SEVERAL: investment, 201812 capital increase CHF23.5m with 3.134m shares at CHF7.5/share |
2018-12-12 |
| SGS–Imprint Analytics: food analysis, 201812– collab strategic partnership isotope analysis for proof of origin + authenticity food testing |
2018-12-12 |
| DenovoMatrix–High-Tech Gründerfonds: investment, 201812 seed financing round from HTGF + TGFS |
2018-12-11 |
| DenovoMatrix–Saxony (govt): investment, 201812 seed financing round from HTGF + TGFS |
2018-12-11 |
| DenovoMatrix–SEVERAL: investment, 201812 seed financing round from HTGF + TGFS |
2018-12-11 |
| Chiesi–Centogene: genetic services, 201812– collab epidemiology study in lysosomal storage diseases with focus on AM by Centogene for Chiesi GmbH |
2018-12-10 |
| genOway–Merck (DE): CRISPR technology, 201812– collab strategic alliance €na incl ww excl license to produce + sell genome-edited rodent models |
2018-12-10 |
| genOway–Merck (DE): CRISPR technology, 202001– collab strategic alliance extention incl adding non-excl license for all non-rodent animal cell models |
2018-12-10 |
| Lonza–General Electric: biologics manufacuturing technology, 201812–2020 supply biologics facility in Guangzhou using KUBio platform by GE Healthcare |
2018-12-10 |
| Alacris–Seedmatch: financial services, 201812– crowdfunding campaign up to €800k via Seedmatch platform |
2018-12-06 |
| Alacris–SEVERAL: investment, 201812– crowdfunding campaign up to €800k via Seedmatch platform |
2018-12-06 |
| Hookipa–Valneva: drug development services, 201812–202111 collab + manufacturing agreem for developm of immunotherapies with Valneva Sweden AB |
2018-12-06 |
| Merck (DE)–Cyclica: drug discovery services, 201812– collab using cloud-based proteome screening platform for small molecule drug development |
2018-12-06 |
| Novartis–Qiagen: molecular companion diagnostics, 201812– collab developm of CDx for alpelisib (BYL719) |
2018-12-06 |
| AC Immune–Hopp Group: investment, 201812 existent investment dievini Hopp owns 27% of AC Immune SA |
2018-12-05 |
| Apogenix–Hopp Group: investment, 201812 existent investment dievini Hopp owns 92% of Apogenix AG |
2018-12-05 |
| Cassiopea–Hopp Group: investment, 201812 existent investment dievini Hopp owns 1% of Cassiopea SpA |
2018-12-05 |
| Cosmo Pharmaceuticals–Hopp Group: investment, 201812 existent investment dievini Hopp owns 5% of Cosmo SpA |
2018-12-05 |
| CureVac–Hopp Group: investment, 201812 existent investment dievini Hopp owns 80% of CureVac AG |
2018-12-05 |
| Heidelberg Pharma–Hopp Group: investment, 201812 existent investment dievini Hopp owns 83% of Heidelberg Pharma AG |
2018-12-05 |
| Immatics–Hopp Group: investment, 201812 existent investment dievini Hopp owns 38% of Immatics GmbH |
2018-12-05 |
| Joimax–Hopp Group: investment, 201812 existent investment dievini Hopp owns 85% of Joimax GmbH |
2018-12-05 |
| Molecular Health–Hopp Group: investment, 201812 existent investment dievini Hopp owns 95% of Molecular Health GmbH |
2018-12-05 |
| Novaliq–Hopp Group: investment, 201812 existent investment dievini Hopp owns 93% of Novaliq GmbH |
2018-12-05 |
| Anagenesis–Alsace (govt): investment, 201812 financing round Series A 1st closing totalling €3m incl existing investor Cap Innov’Est |
2018-12-04 |
| Anagenesis–Boehringer: investment, 201812 financing round Series A 1st closing totalling €3m incl new investor BIVF |
2018-12-04 |
| Anagenesis–SEVERAL: investment, 201812 financing round Series A €3m 1st closing from BIVF + Cap Innov’Est |
2018-12-04 |
| Boehringer–Domain Therapeutics: drug discovery services, 201812– collab + license agreem €na discovery of GPCR-targeting CNS drugs |
2018-12-04 |
| Leo Pharma–Evotec: drug discovery services, 201812– collab €na integrated drug discovery to generate leads against innovative dermatic targets |
2018-12-04 |
| Argenx–JnJ: investment, 201812 investment $200m of 1.767m new shares at €100.02/share representing 4.68% shareholding by JJDC |
2018-12-03 |
| JnJ–Argenx: cusatuzumab, 201812–202106 collab + license agreem ww with Cilag GmbH up to $1.6b incl $300m upfront cash TERMINATED 6/21 |
2018-12-03 |
| Dispendix–Cellink: investment, 201812 acquisition €5m of Dispendix GmbH by Cellink AB |
2018-12-01 |
| Resistell–SEVERAL: investment, 201812 seed financing round CHF850k |
2018-12-01 |
| Hookipa–DarwinHealth: personalised medicine, 201811– collab research + license agreem to develop I-O treatments using systems biology |
2018-11-28 |
| Jecure Therapeutics–Roche: investment, 201811 acquisition of Jecure by Genentech from Versant Ventures |
2018-11-27 |
| Spindiag–SEVERAL: investment, 201811 financing round Series A €3m |
2018-11-27 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
1 2 3 ... 24 25 26 ... 48 49 50 
Date![Picture [iito] Fighting Customers 650x100px](/banner/iito-business-intelligence-20211013-650-100-summer-banner-series-fighting-customers.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
